scholarly journals Prognostic significance of the Central Tumor Size (CTS) in Cervical Cancer (CC) stages IIb and IIIb: What should we do with the FIGO staging system and therapeutic strategies?

2021 ◽  
Vol 5 (1) ◽  
pp. 002-005
Author(s):  
Soderini Alejandro ◽  
Aragona Alejandro ◽  
Quintaie Agustin ◽  
Moschen Horacio ◽  
Mendez Martín

Cervical cancer constitutes an issue in public health, becoming the leading cause of death by cancer in women between 20-40 years of age in Latin America. In Argentina 5000 new cases are diagnosed each year, where more than 56% are in advanced stages. The aim of the present current opinion or critical review article is to remark the importance of the prognostic significance of the Central Tumor Size in stages IIB and IIIB cervical cancer, as well as to propose a new FIGO Staging System for Cervical cancer and trying to find out a role for the different therapeutic strategies for those cases.

2021 ◽  
Vol 60 (6) ◽  
pp. 1054-1058
Author(s):  
Daiken Osaku ◽  
Hiroaki Komatsu ◽  
Masayo Okawa ◽  
Yuki Iida ◽  
Shinya Sato ◽  
...  

2020 ◽  
Vol 158 (2) ◽  
pp. 266-272
Author(s):  
Roman E. Zyla ◽  
Lilian T. Gien ◽  
Danielle Vicus ◽  
Ekaterina Olkhov-Mitsel ◽  
Jelena Mirkovic ◽  
...  

2020 ◽  
Vol 156 (1) ◽  
pp. 85-92 ◽  
Author(s):  
Kyra N. McComas ◽  
Anna M. Torgeson ◽  
Bryan J. Ager ◽  
Christopher Hellekson ◽  
Lindsay M. Burt ◽  
...  

2005 ◽  
Vol 15 (4) ◽  
pp. 573-582 ◽  
Author(s):  
K. Narayan

FIGO staging of cervical cancer is based on anatomic compartmental spread of cervical cancer. This was necessary in the evaluation of surgical resectability in each patient. Even if the surgical resection was not deemed satisfactory, surgical findings and subsequent accurate anatomic pathology findings could be used to prescribe tailored adjuvant therapies. Recently, the management of cervical cancer has been influenced by the evidence from several surgical-pathologic studies and phase II and III combined modality treatment trials. However, the patient selection criteria used in these clinical studies were almost always refined by modern medical imaging and surgical techniques not prescribed in the FIGO staging system. The results obtained from these studies would not correlate with those from the patient population similarly treated but selected strictly along the FIGO staging criteria. This selective, heterogenous, and arbitrary refinement of FIGO staging has certainly given insight into cervical cancer biology but in the process has rendered the current FIGO staging of this disease quite inadequate. Prior knowledge of these factors through modern imaging in these patients could be used in staging and selecting the optimum treatment modality while minimizing the treatment-related morbidity. A magnetic resonance imaging-assisted FIGO staging system for cervical cancer as proposed here could be used for selecting patients appropriately for a given treatment package


2017 ◽  
Vol 473 ◽  
pp. 198-203 ◽  
Author(s):  
Ru-ru Zheng ◽  
Xiao-xiu Huang ◽  
Chu Jin ◽  
Xin-xin Zhuang ◽  
Le-chi Ye ◽  
...  

2021 ◽  
Author(s):  
Xingtao Long ◽  
Qi Zhou ◽  
Dongling Zou ◽  
Dong Wang ◽  
Jingshu Liu ◽  
...  

Abstract Purpose We aimed to validate the prognostic performance of the 2018 International Federation of Gynecology and Obstetrics(FIGO) IIIC staging system for patients with cervical cancer. Methods We conducted a retrospective analysis of patients with stage III cervical cancer according to the 2018 FIGO staging system who received standardized treatment from January 2011 to December 2014. Results Multivariable analysis revealed that stage IIIC1 was not significantly associated with increased risk of death compared with stages IIIA (hazard ratio [HR] = 1.432; 95% confidence interval [CI]: 0.867 to 2.366; P = 0.161) and IIIB (HR = 1.261; 95% CI: 0.871 to 1.827; P = 0.219). Stage IIIC2 was an independent indicator of increased risk of mortality compared with stages IIIA (HR = 2.958; 95% CI :1.757 to 4.983; P < 0.001) and IIIB (HR = 2.606; 95% CI: 1.752 to 3.877; P < 0.001). We stratified patients with stage IIIC1 according to T stage and compared survival outcomes. Stage IIIC1 (T1) was associated with longer 5-year overall survival (OS) compared with stages IIIA (P = 0.004) or IIIB (P < 0.001). An optimal cut-off value (= 2) was established for predicting the prognosis of stage IIIC1p(T1/T2a), which was associated with the number of pelvic lymph nodes metastases (PLNMs). Patients with stage IIIC1pN1-2 experienced longer 5-year OS compared those with stages IIIA (P = 0.01) or IIIB (P < 0.001). Conclusion Patients with stage IIIC1 cervical cancer exhibited heterogeneous clinical characteristics reflecting their variable prognoses, depending on T-stage and the extent of PLNMs


Sign in / Sign up

Export Citation Format

Share Document